Background-In patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention, a suboptimal degree of platelet inhibition for the first 2 hours after the standard 60 mg loading dose of prasugrel has been described. Methods and Results-In a prospective, 3-center, nonrandomized, controlled study, 2 sequential groups of P2Y12 inhibitornaive consecutive patients were loaded with either 100 mg (n=47) or 60 mg (n=35) of prasugrel. Platelet reactivity was assessed by VerifyNow at hours 0, 0.5, 1, 2, and 4. At hour 2, there was a strong trend for the primary end point of platelet reactivity (in P2Y12 reaction units) to be lower (least squares estimates of the mean difference [95% confidence interval], −45.5 [−91.2 to 0.3]; P=0.051), whereas platelet reactivity percentage inhibition (median, first to third quartile) was higher (75.5% [24%-91.8%] versus 23.5% [0%-78.3%]; P=0.02) in the 100-mg compared with 60-mg loading dose group. At hour 2, prasugrel 100 mg over 60 mg loading dose significantly reduced high platelet reactivity rates from 28.6% to 8.5% (≥230 P2Y12 reaction units threshold; P=0.036) and from 31.4% to 10.6% (≥208 P2Y12 reaction units threshold; P=0.024), whereas resulted in lower rate of ≤20% platelet inhibition (23.4% versus 51.4%; P=0.009) . Conclusions-In patients with ST-segment-elevation myocardial infarction treated with primary percutaneous coronary intervention, a higher (100 mg) than the standard loading dose of prasugrel results in greater and more consistent platelet inhibition, yet this will need to be further validated in additional studies. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01835353.
P rasugrel is an oral third-generation thienopyridine with rapid intestinal absorption and intestinal/hepatic metabolism. Peak plasma concentrations (C max ) of prasugrel active metabolite occur ≈30 minutes after administration of a 60to 75-mg loading dose (LD) in healthy volunteers, whereas the exposure to its metabolites is consistent with dose proportionality. 1, 2 In healthy subjects and in patients with stable coronary artery disease, a 60-mg LD of prasugrel results in a significant antiplatelet effect at 30 minutes when no effect is detectable with 600-mg LD of clopidogrel. 3, 4 Furthermore, in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) and participating in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI), 38 platelet substudy, vasodilator-stimulated phosphoprotein index, and maximal platelet aggregation to 20 μmol/L ADP were lower in prasugrel than in clopidogrel-treated patients at 1 to 2 hours post PCI (≥1 hour after LD). 5 Patients with ST-segment-elevation myocardial infarction (STEMI) represent an extremely challenging cohort in whom a highly thrombotic milieu is observed. 6 Platelet reactivity (PR) is increased, particularly during the acute phase and therefore, early and strong platelet inhibition is of utmost importance. 7 A negligible level of platelet inhibition at the time of intervention has been reported in the great majority of patients with STEMI after prehospital administration of clopidogrel. 8 Data on prasugrel pharmacodynamics in the early hours of STEMI and periprimary PCI are limited. After a 60-mg LD of prasugrel, a suboptimal degree of early platelet inhibition for the first 2 hours was described, whereas simultaneous tirofiban high-dose bolus administration was able to bridge this interval of incomplete platelet inhibition. 9 In a randomized comparison of the pharmacodynamic action of ticagrelor 180 mg versus prasugrel 60 mg in patients with STEMI undergoing primary PCI by our group, a delayed onset of action for both agents was found with 59.3% and 30.8% of patients exhibiting high PR (HPR, P2Y12 reaction units [PRU]≥230) at hours 1 and 2 post 60-mg LD of prasugrel, respectively. 10 Similar results have been reported by Parodi et al. 11 We raised, therefore, the hypothesis that a higher than the standard LD of prasugrel might lead to a more rapid and stronger platelet inhibition. In this study, we aimed to assess the onset and magnitude of antiplatelet action provided by 100 mg compared with 60-mg LD of prasugrel in patients with STEMI undergoing primary PCI.
Methods

Study Protocol
During 2 sequential periods between July 2012 and July 2013, we performed a prospective, 3-center, nonrandomized active-controlled study in patients with STEMI with ischemic pain of <12 hours undergoing primary PCI with stent implantation. Eligible patients were loaded with either 100 mg (experimental group) or 60 mg (active comparator group) of prasugrel during the first 7-month and the second 5-month period, respectively. As prasugrel doses >75 mg had not been previously used, the selection of the 100-mg dose was exploratory and arbitrary. Overall, 241 consecutive patients were screened as potential candidates for participation in the study. Patients were excluded if they met any of the following criteria: prior stroke/transient ischemic attack, weight <60 kg, age ≥75 years, bleeding diathesis, chronic oral anticoagulation treatment, contraindications to or previous antiplatelet treatment other than aspirin, loading with P2Y12 inhibitor before screening, PCI or coronary artery bypass grafting <3 months, hemodynamic instability, coronary anatomy not suitable for primary PCI, platelet count <100 000/μL, hematocrit <30%, creatinine clearance <30 mL/min, severe hepatic dysfunction, and periprocedural IIb/IIIa inhibitor administration. Vomiting after prasugrel loading and before blood sampling at hour 1 was also an exclusion criterion. A study flow chart is shown in Figure 1 . Aspirin 325 mg LD was given to all patients at first medical contact. Unfractionated heparin and bivalirudin administration was left at the operator's discretion.
Prasugrel LD was administered in all patients at the catheterization laboratory, after coronary angiography and before PCI, immediately after baseline blood sampling (hour 0). Blood sampling was also performed at hours 0.5, 1, 2, and 4 thereafter. In all cases peripheral venous blood was drawn with a loose tourniquet through a short venous catheter inserted into a forearm vein. The first 2 to 4 mL of blood was discarded to avoid spontaneous platelet activation and blood was collected in 3.2% citrate (1.8-mL draw plastic Vacuette tubes; Greiner, Monroe, NC). Platelet function testing was performed with the VerifyNow (Accumetrics Inc, San Diego, CA) point-of-care P2Y12 function assay as previously reported. 12 PR results are reported in PRU, BASE, and percentage inhibition. The percentage inhibition is calculated as: ([BASE−PRU]/BASE)×100.
End Points
The primary end point was PR (in PRU) at hour 2. PR (in PRU) at all the other time points of the study were secondary end points. Additional secondary end points were HPR rates with thresholds ≥230 PRU and ≥208 PRU 13, 14 along with platelet inhibition ≤20% rate at all the study's time points. Because no HPR thresholds predicting ischemic events have been determined to date specifically for STEMI populations, the ones we used were obtained from studies without STEMI patients.
Documentation of major adverse cardiovascular events-death, myocardial infarction, stroke, urgent revascularization-and serious adverse events (bleeding, other adverse events) was performed until 1-month follow up. Bleeding Academic Research Consortium classification was used for bleeding events. 15
Statistical Analysis
Categorical data are presented as frequencies and group percentages. Continuous data with normal and skewed distribution are presented as mean±SD and medians (first to third quartiles), respectively. The Kolmogorov-Smirnov test was used to examine data distribution normality. Two-sample t test and Fisher exact test were used for comparison of normally distributed continuous and categorical data, respectively. The Mann-Whitney U test was used for comparison of skewed continuous data.
Propensity score of exposure to prasugrel 100 mg (versus 60 mg) was estimated with a logistic regression model fit with diabetes mellitus, bivalirudin use, creatinine clearance <60 mL/m, and body mass index (classified into the following groups: 18.5-24.9, 25-29.9, and 30-34.9). PR values at all the study's time points were analyzed separately via a mixed-effect model with treatment as fixed effect, center and patient as random effects, PR at baseline, and propensity score as covariates. Least squares estimates of the mean difference are presented, with 95% confidence intervals (CI) and a 2-sided P value for the treatment effect. PR percentage inhibition was analyzed with Mann-Whitney test and is presented as medians (first to third quartiles). Adjusted estimates for HPR and inhibition ≤20% rates (presented as risk ratios with corresponding P values) were derived from modified log-Poisson regression models with robust variance estimator, with treatment and quintiles of propensity score as fixed effects. All tests were 2-tailed and statistical significance was considered for P values <0.05. All statistical analyses were performed
WHAT IS KNOWN
• In patients with ST-segment-elevation myocardial infarction a highly thrombotic milieu is observed and early and strong platelet inhibition is of utmost importance.
• A suboptimal degree of platelet inhibition for up to 2 hours after the standard 60-mg loading of prasugrel is observed in patients undergoing primary percutaneous coronary intervention.
WHAT THE STUDY ADDS
• At hour 2 after loading with 100 mg of prasugrel there is a strong trend for platelet reactivity to be lower than when loading with standard dose.
• Platelet reactivity percentage inhibition is higher, whereas high platelet reactivity and ≤20% platelet inhibition rates are lower 2 hours post loading with 100 mg compared with 60 mg of prasugrel. 
Sample Size Calculation
Based on previously published data on the early pharmacodynamic response of 60-mg LD of prasugrel in the clinical setting of STEMI, 10 we hypothesized that 100-mg LD of prasugrel would be superior to 60-mg LD of prasugrel with a PR absolute difference of ≥50 PRU at 2 hours post randomization, with the assumption that the within-group SD of PR will be 65 PRU and that the covariate (baseline PR) has an R 2 of 0.1. Choosing a power of 90% and a 2-sided alpha-level of 0.05, ≥66 patients in total (33 in each group) would be required to reach statistical significance.
The study protocol was approved by the Ethics Committee of each participant hospital and conducted according to the principles of the Declaration of Helsinki. All patients provided written informed consent before enrollment.
Results
Overall, prasugrel pharmacodynamics was analyzed in 47 and 35 patients treated with high and standard LD, respectively. Demographic and clinical characteristics of patients did not differ significantly between groups (Table 1) . Complete procedural success (TIMI flow grade 3) was achieved in all but 1 patient (from the high LD group) in whom TIMI flow grade 1 persisted despite intervention.
Propensity score model had fair discriminative power (C-statistic=0.69; 95% CI, 0.57-0.81; P=0.004). The distribution of propensity scores by treatment group is shown in the Figure in the Data Supplement. PR (PRU and percentage inhibition) at 0.5, 1, 2, and 4 hours post prasugrel LD in the 2 groups is shown in Table 2 . There was a strong trend for the primary end point of PR (PRU) at hour 2 to be lower with prasugrel 100 compared with prasugrel 60 mg (least squares estimates of the mean difference [95% CI], −45.5 [−91.2 to 0.3]; P=0.051). At hour 4, PR (PRU) was also lower in the 100-mg versus 60-mg LD group with a least squares estimates of the mean difference (95% CI) of −31.2 (−56.8 to −5.6), P=0.02. At hours 1 and 2, percentage inhibition was higher by prasugrel 100 compared with prasugrel 60 mg LD. Individual PR values are depicted in Figure 2 .
HPR and ≤20% inhibition rates are depicted in Figure 3 and in the Table in the Data Supplement. At hour 2, prasugrel 100 mg resulted in significantly lower than prasugrel 60 mg HPR rates (using either ≥230 PRU or ≥208 PRU thresholds) as well as ≤20% inhibition rate.
During in-hospital observation, Bleeding Academic Research Consortium type 1 (bruising) and 2 (access site hematoma) was observed in 4 (3 in the 100-mg and 1 in the 60-mg LD group) and 2 patients (in the 100-mg LD group), respectively. At 1-month follow-up, 1 patient from 100-mg LD arm had a Bleeding Academic Research Consortium type 3a bleeding event (from the gastrointestinal tract), and 25 patients (18 in 100-mg LD and 7 in 60-mg LD arm; P value=0.09) experienced a Bleeding Academic Research Consortium type 1 bleeding event (bruising in most cases). No major adverse cardiovascular events occurred in either treatment arm in-hospital or at 1-month follow-up. Data are expressed as mean±SD, medians (first to third quartiles) or n (%). UFH dose was significantly lower in bivalirudin (n=42) vs UFU alone (n=40) treated patients 5369±2650 IU vs 8312±2492 IU, respectively, P<0.001. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; FHCAD, family history of coronary artery disease; IU, international units; NA, not applicable; PCI, percutaneous coronary intervention; PPIs, proton pump inhibitors; PRU, P2Y12 reaction units; and UFH, unfractionated heparin.
Discussion
We have tried to expedite the onset of action of prasugrel in patients with STEMI treated with primary PCI by loading them with a higher (100 mg) than the standard 60-mg LD. We found that the high LD regimen is followed by a more potent platelet inhibition 2 hours post loading, compared with that provided by the standard dose, as reflected by a trend for a lower PR (in PRU), a higher percentage inhibition and lower HPR and ≤20% inhibition rates. Our results represent the first, to our knowledge, successful effort to achieve a stronger and more consistent antiplatelet action in patients with STEMI undergoing primary PCI by modifying the recommended for clinical use LD of an orally administered P2Y12 inhibitor.
Prasugrel is a third-generation thienopyridine with intestinal plus a single-step hepatic metabolic activation able to provide fast antiplatelet activity after 60-mg LD in healthy volunteers and in patients with stable coronary artery disease or acute coronary syndrome. [3] [4] [5] However, in the setting of STEMI, a delayed onset of action has been described for all the 3 orally administered P2Y12 inhibitors. [9] [10] [11] 16, 17 Findings in our control group (60 mg LD) were in line with previous observations. [9] [10] [11] Specific conditions accompanying STEMI (such as increased sympathetic tone, systemic vasoconstriction, disturbed gastrointestinal motility, morphine use, etc) have been implicated to affect oral antiplatelet agents' absorption, metabolism, and subsequent pharmacokinetics and pharmacodynamics. 11, 17 
Previous Pharmacodynamic Studies in STEMI to Bridge the Early Antiplatelet Action Gap
Efforts to bridge the gap in antiplatelet action observed early after the administration of oral P2Y12 inhibitors in patients with STEMI have already been reported. Valgimigli et al 9 first described a suboptimal degree of early platelet inhibition for the first 2 hours after 60-mg LD of prasugrel. The simultaneous tirofiban high-dose bolus administration was able to bridge this interval of incomplete platelet inhibition. Practical issues or bleeding potential of IIb/IIIa coadministration with a potent P2Y12 inhibitor may be of concern and hamper the further development of this strategy. Ticagrelor is an orally administered, potent and with rapid onset of antiplatelet action P2Y12 inhibitor. In a recent study, we were unable to demonstrate an expedited effect by doubling (360 mg) the LD of compared with the standard 180-mg LD of ticagrelor in patients with STEMI undergoing primary PCI. 18
Findings and Interpretation
Accurate interpretation of our findings is limited the lack of concomitant prasugrel pharmacokinetic evaluation. Prasugrel requires intestinal absorption with efflux via P-glycoprotein PR (in PRU) is presented as LSE (95% CI); PR percentage inhibition is presented as medians (first to third quartiles). CI indicates confidence interval; LD, loading dose; LSE, least squares estimates; PR, platelet reactivity; and PRU, P2Y12 reaction units. Figure 2 . Individual values of platelet reactivity (PR) at hours 0, 0.5, 1, 2, and 4 post prasugrel 100 mg loading dose (LD; green dots) and 60 mg LD (gray dots), as assessed with the VerifyNow assay in P2Y12 reaction unit (PRU). A trend for lower PR with the high than the standard dose at hour 2 is apparent. Lines represent least squares estimates and error bars 95% confidence interval.
(encoded by ABCB1, also known as MDR1). It is unknown whether alterations in P-glycoprotein expression/function occur in the setting of hyper-adrenergic conditions such as in STEMI potentially affecting prasugrel (either 60 mg or 100 mg) absorption. A dose-dependent relatively higher formation of prasugrel's active metabolite by intestinal CYP3A (mainly), CYP2C9, and CYP2C19 might also be implicated. 19 The higher and more consistent platelet inhibition provided by the high LD we used makes P-glycoprotein or intestinal/ hepatic enzymes involved in prasugrel metabolism saturation unlikely, at least in most cases. The genetic influence of ABCB1 C3435T polymorphisms has also been implicated in prasugrel's absorption, although this effect has not been specifically addressed in STEMI and certainly not when 100-mg LD is administered. 20 The high LD we used represents, to the best of our knowledge, the highest prasugrel dose ever given in humans, since previously doses ≤75 mg had been administered. 2 It is unknown whether a higher than 100-mg LD might achieve an earlier platelet inhibition or at which point a saturation effect might occur. Even more importantly, the safety of the 100-mg LD or a higher dose is questionable.
In the relatively small cohort of our STEMI population, with the known prothrombotic diathesis and the documented delayed onset of antiplatelet action exhibited by the standard prasugrel LD, the high LD was well tolerated without any obvious excess of clinically significant bleeding.
Implications
Without adopting intravenous antiplatelet agents, the strategy we have described seems to reduce PR in most cases. After 100-mg LD of prasugrel, ≈90% of patients had at 2 hours PR values below the thresholds associated with ischemic events, with the caveat that the latter have been obtained in different than STEMI clinical settings. Whether this stronger platelet inhibition is followed by improvement initially in surrogate end points, that is, ST resolution, enzymatic or MRI infarct size and ultimately in clinical benefit requires further investigation. In the Comparison of Prasugrel at the Time of PCI or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction (ACCOAST) study, no STEMI patients were included. 21 Therefore, there remains a lack of data in the STEMI setting to address whether a relative benefit of upstream prasugrel administration exists. However, it is likely that the pharmacodynamic delay may be less of an issue if prasugrel is administered as early as possible, that is, in the ambulance. A larger number of patients should be also studied to provide more meaningful evidence on the safety of the high LD regimen we used. Serious bleeding events occur frequently in patients with STEMI undergoing primary PCI with a negative impact on long-term outcome, even greater than reinfarction. 22 This emphasizes the need for minimizing bleeding complications, which may occur after standard and, even more, high prasugrel doses. Of note, cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an intravenous antagonist of the P2Y12 receptor characterized by rapid, potent, predictable, and reversible platelet inhibition. 23, 24 Therefore, cangrelor seems ideal, at least theoretically, for use in the early hours of STEMI and immediate platelet inhibition. In the recently published Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION)-PHOENIX trial, the primary efficacy end point of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours was reduced by cangrelor versus clopidogrel with adjusted odds ratio (95% CI) 0.78 (0.66-0.93), P=0.005. 25 However, this study included only a minority of patients with STEMI and clopidogrel, was a rather weak antiplatelet comparator. After the results of the present study, we think that a comparison of a cangrelor involving strategy versus standard, or even better, high LD of prasugrel in patients with STEMI is tempting. Beyond pharmacodynamics, further elucidation of the usefulness of earlier platelet inhibition in patients with STEMI is expected by the ongoing Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study (NCT01347580). In this study, a strategy of prehospital versus in-hospital ticagrelor administration is tested with clinical surrogate end points like pre-angiography TIMI flow and ST resolution as primary outcomes. 26 
Study Limitations
This was a pharmacodynamic study and no conclusions or suggestions of clinical use can be drawn. Only 1 method of platelet function testing has been used (VerifyNow). However, this method is the most validated one and correlates well with light transmittance aggregometry. In addition, a point-of care platelet function assay is easily available on a 24/7 basis allowing serial measurements and enrollment of consecutive patients with STEMI. Our study was not randomized. However, demographic and clinical characteristics were balanced between groups. Propensity score adjustment was used, nevertheless we cannot rule-out residual bias because of either unmeasured confounding or overadjustment. A strong trend for difference of the primary end point was found between groups. A larger sample size would increase the study power and would probably result in a statistically significant difference while allowing adjustment for more confounders in propensity score model.
Conclusions
In patients with STEMI treated with primary PCI, the administration of a higher than the standard LD of prasugrel seems to lead to greater and more consistent reduction in PR. Undoubtedly, the trade-off point between benefit and safety of the proposed strategy merits further investigation.
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